IN187317B - - Google Patents

Info

Publication number
IN187317B
IN187317B IN517DE2001A IN187317B IN 187317 B IN187317 B IN 187317B IN 517DE2001 A IN517DE2001 A IN 517DE2001A IN 187317 B IN187317 B IN 187317B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Peter James Dunn
Albert Shaw Wood
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10795332&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN187317(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Priority to IN517DE2001 priority Critical patent/IN187317B/en
Publication of IN187317B publication Critical patent/IN187317B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IN517DE2001 1996-06-14 2001-04-24 IN187317B (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN517DE2001 IN187317B (fr) 1996-06-14 2001-04-24

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9612514.1A GB9612514D0 (en) 1996-06-14 1996-06-14 Novel process
IN1548DE1997 IN187350B (fr) 1996-06-14 1997-06-10
IN517DE2001 IN187317B (fr) 1996-06-14 2001-04-24

Publications (1)

Publication Number Publication Date
IN187317B true IN187317B (fr) 2002-03-23

Family

ID=10795332

Family Applications (5)

Application Number Title Priority Date Filing Date
IN1548DE1997 IN187350B (fr) 1996-06-14 1997-06-10
IN518DE2001 IN187318B (fr) 1996-06-14 2001-04-24
IN517DE2001 IN187317B (fr) 1996-06-14 2001-04-24
IN520DE2001 IN187320B (fr) 1996-06-14 2001-04-24
IN519DE2001 IN187319B (fr) 1996-06-14 2001-04-24

Family Applications Before (2)

Application Number Title Priority Date Filing Date
IN1548DE1997 IN187350B (fr) 1996-06-14 1997-06-10
IN518DE2001 IN187318B (fr) 1996-06-14 2001-04-24

Family Applications After (2)

Application Number Title Priority Date Filing Date
IN520DE2001 IN187320B (fr) 1996-06-14 2001-04-24
IN519DE2001 IN187319B (fr) 1996-06-14 2001-04-24

Country Status (48)

Country Link
US (2) US5955611A (fr)
EP (2) EP0916675B1 (fr)
JP (2) JP2866841B2 (fr)
KR (1) KR100207352B1 (fr)
CN (2) CN1106399C (fr)
AP (1) AP717A (fr)
AR (1) AR003401A1 (fr)
AT (2) ATE182150T1 (fr)
AU (1) AU697684B2 (fr)
BG (1) BG62554B1 (fr)
BR (1) BR9703580A (fr)
CA (1) CA2207694C (fr)
CO (1) CO4780028A1 (fr)
CZ (1) CZ290942B6 (fr)
DE (2) DE69723846T2 (fr)
DK (2) DK0916675T3 (fr)
DZ (1) DZ2247A1 (fr)
EA (1) EA000102B1 (fr)
EG (1) EG24123A (fr)
ES (2) ES2134051T3 (fr)
GB (1) GB9612514D0 (fr)
GR (1) GR3031087T3 (fr)
HK (1) HK1033459A1 (fr)
HN (1) HN1997000072A (fr)
HR (1) HRP970326B1 (fr)
HU (1) HU224497B1 (fr)
ID (1) ID18745A (fr)
IL (3) IL121000A (fr)
IN (5) IN187350B (fr)
IS (2) IS1922B (fr)
MA (1) MA24205A1 (fr)
MX (1) MX9704433A (fr)
NO (2) NO304551B1 (fr)
NZ (1) NZ328084A (fr)
OA (1) OA10426A (fr)
PE (2) PE20011303A1 (fr)
PL (1) PL189333B1 (fr)
PT (1) PT916675E (fr)
RS (2) RS49924B (fr)
SA (1) SA97180124B1 (fr)
SG (1) SG50024A1 (fr)
SI (2) SI0916675T1 (fr)
SK (5) SK283897B6 (fr)
TN (1) TNSN97102A1 (fr)
TR (1) TR199700470A2 (fr)
UA (1) UA27085C2 (fr)
UY (2) UY24585A1 (fr)
ZA (1) ZA975259B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060222647A1 (en) * 1993-05-27 2006-10-05 Beavo Joseph A Methods and compositions for modulating the activity of PDE5
EP0977756A1 (fr) * 1997-04-25 2000-02-09 Pfizer Limited PYRAZOLOPYRIMIDINONES INHIBANT LA PHOSPHODIESTERASE D'ACIDE GUANOSINE-3'5'-MONOPHOSPHATE CYCLIQUE (cGMP PDE5) S'UTILISANT POUR TRAITER DES DYSFONCTIONS SEXUELLES
EP0992240A4 (fr) * 1997-05-29 2003-04-16 Mochida Pharm Co Ltd Agent therapeutique destine a traiter l'anerection
US6399618B1 (en) 1997-07-09 2002-06-04 Cardiome Pharma Corp Compositions and methods for modulating sexual activity
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
DE19881732D2 (de) 1997-11-12 2000-08-24 Bayer Ag 2-Phenyl-substituierte Imidazotriazinone als Phoshodiesterase Inhibitoren
CN1134442C (zh) 1998-04-20 2004-01-14 美国辉瑞有限公司 吡唑并嘧啶酮cGMP PDE5抑制剂、其制备方法及用途及中间体
CA2235642C (fr) 1998-05-15 2007-11-13 Torcan Chemical Ltd. Methodes pour preparer le sildenafil
DK1109814T3 (da) * 1998-09-04 2004-08-02 Ortho Mcneil Pharm Inc 5-Heterocyclylpyrazolo[4,3-d]pyrimidin-7-oner til behandling af mandlig erektil dysfunktion
GB9822238D0 (en) * 1998-10-12 1998-12-09 Pfizer Ltd Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823102D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823103D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
KR100353014B1 (ko) * 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
WO2000078760A1 (fr) * 1999-06-21 2000-12-28 The Biochemical Pharmaceutical Factory Of Zhuhai Sez Procede de preparation de sildenafil, agent et procede d'obtention d'un comprime mixte a base de sildenafil et de chlorhydrate d'apomorphine
CN1094492C (zh) * 1999-06-21 2002-11-20 杭州神鹰医药化工有限公司 西地那非的制备方法
CN1077108C (zh) * 1999-07-13 2002-01-02 成都地奥制药集团有限公司 用于制备药物昔多芬的前体化合物
WO2001019827A1 (fr) * 1999-09-13 2001-03-22 Cipla Ltd. Nouveau procede de synthese du citrate de sildefanile
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
SK4562002A3 (en) 1999-10-11 2003-04-01 Pfizer 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)- dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors
US6667398B2 (en) 2000-06-22 2003-12-23 Pfizer Inc Process for the preparation of pyrazolopyrimidinones
GB0015462D0 (en) * 2000-06-22 2000-08-16 Pfizer Ltd Novel process for the preparation of pyrazolopyrimidinones
JP2004501154A (ja) * 2000-06-22 2004-01-15 ファイザー・インク ピラゾロピリミジノン製造のための新規方法
US6730786B2 (en) 2000-06-22 2004-05-04 Pfizer Inc Process for the preparation of pyrazolopyrimidinones
US6407259B1 (en) 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
YU51701A (sh) * 2000-07-28 2003-12-31 Pfizer Inc. Postupak za dobijanje jedinjenja pirazola/4,3-d/ pirimidin-7-ona i njihovih derivata
EP1176142A1 (fr) * 2000-07-28 2002-01-30 Pfizer Inc. Procédé pour la préparation de pyrazoles
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
CN1127506C (zh) * 2001-06-29 2003-11-12 刘宝顺 一种治疗阳痿的新化合物
CN1781920A (zh) * 2001-08-28 2006-06-07 先灵公司 多环鸟嘌呤磷酸二酯酶v抑制剂
EP1719772A1 (fr) 2002-05-31 2006-11-08 Schering Corporation Procédé de préparation d'inhibiteurs de la phosphodiesterase v de la xanthine et leur précurseurs
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
CN100374441C (zh) 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
CN100360531C (zh) * 2003-12-18 2008-01-09 中国人民解放军军事医学科学院放射与辐射医学研究所 用于预防或治疗阳萎和性冷淡的新吡唑并嘧啶类化合物
ATE387203T1 (de) * 2004-01-05 2008-03-15 Teva Pharma Prozesse zur herstellung von sildenafil-base und zitratsalz
EP1779852A3 (fr) * 2004-01-05 2007-05-09 Teva Pharmaceutical Industries Ltd. Procedes de fabrication de sildenafil base et de son sel citrate
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
WO2008074194A1 (fr) * 2006-12-21 2008-06-26 Topharman Shanghai Co., Ltd. Procédé de préparation du sildénafil et de ses intermédiaires
ES2310144B1 (es) 2007-06-15 2010-01-12 Galenicum Health, S.L. Intermedios para la preparacion de un inhibidor de la fosfodiesterasa tipo 5.
WO2010067140A1 (fr) 2008-12-12 2010-06-17 Siegfried Rhein S.A. De C.V. Composition de sildénafil à libération pulsée et son procédé de préparation
MX2010006227A (es) 2010-06-07 2011-12-14 World Trade Imp Exp Wtie Ag Nuevos derivados 1,4-diazepanos, inhibidores de pde-5.
CN102993205B (zh) * 2012-12-27 2015-04-15 华润赛科药业有限责任公司 一种高收率制备高纯度西地那非游离碱的纯化方法
CN103044330B (zh) * 2013-01-14 2018-11-13 常州亚邦制药有限公司 西地那非中间体4-氨基-1-甲基-3-正丙基吡唑-5-甲酰胺的绿色合成新工艺
CN105085526B (zh) * 2014-05-15 2017-08-01 重庆圣华曦药业股份有限公司 一种改进的西地那非制备方法
CN105753870B (zh) * 2016-04-01 2018-05-22 重庆康刻尔制药有限公司 一种西地那非杂质f及其制备方法和应用
WO2017168174A1 (fr) 2016-04-02 2017-10-05 N4 Pharma Uk Limited Nouvelles formes pharmaceutiques du sildénafil
CN105837578A (zh) * 2016-04-05 2016-08-10 重庆康刻尔制药有限公司 一种西地那非杂质d的合成方法
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
CN113493459B (zh) * 2020-04-07 2022-12-13 广州白云山医药集团股份有限公司白云山制药总厂 Pde5抑制剂化合物及其制备方法和应用
CN112961160A (zh) * 2021-03-05 2021-06-15 遂成药业股份有限公司 一种西地那非的改良合成工艺
CN113754612B (zh) * 2021-10-26 2023-09-26 山东安舜制药有限公司 一种西地那非中间体的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871843A (en) * 1983-10-18 1989-10-03 Dropic-Societe Civile De Gestion De Droits De Propriete Industrielle Cyclic benzenesulfonamides, process for their preparation and their use as active substance of pharmaceutical compositions
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
EP0977756A1 (fr) * 1997-04-25 2000-02-09 Pfizer Limited PYRAZOLOPYRIMIDINONES INHIBANT LA PHOSPHODIESTERASE D'ACIDE GUANOSINE-3'5'-MONOPHOSPHATE CYCLIQUE (cGMP PDE5) S'UTILISANT POUR TRAITER DES DYSFONCTIONS SEXUELLES
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase

Also Published As

Publication number Publication date
EA199700061A1 (ru) 1997-12-30
MA24205A1 (fr) 1997-12-31
IS1922B (is) 2004-03-15
EP0916675A3 (fr) 1999-07-14
IN187320B (fr) 2002-03-23
DE69700321D1 (de) 1999-08-19
KR100207352B1 (en) 1999-07-15
PL320555A1 (en) 1997-12-22
PT916675E (pt) 2003-11-28
HU224497B1 (hu) 2005-10-28
IL125411A (en) 2000-02-29
SK283897B6 (sk) 2004-04-06
ES2201397T3 (es) 2004-03-16
HUP9701048A3 (en) 2000-10-30
IS1923B (is) 2004-03-15
IN187318B (fr) 2002-03-23
CO4780028A1 (es) 1999-05-26
CN1282740A (zh) 2001-02-07
DK0812845T3 (da) 1999-11-29
NO972481L (no) 1997-12-15
AU697684B2 (en) 1998-10-15
EA000102B1 (ru) 1998-08-27
UA27085C2 (uk) 2000-02-28
JPH1081688A (ja) 1998-03-31
BG62554B1 (bg) 2000-02-29
CZ290942B6 (cs) 2002-11-13
NZ328084A (en) 1998-08-26
EP0916675B1 (fr) 2003-07-30
NO972481D0 (no) 1997-05-30
SK283895B6 (sk) 2004-04-06
BR9703580A (pt) 1998-11-10
TNSN97102A1 (fr) 2005-03-15
PE20011303A1 (es) 2001-12-25
AP9701009A0 (en) 1997-07-31
NO985064D0 (no) 1998-10-30
HN1997000072A (es) 1997-12-26
KR980002051A (ko) 1998-03-30
ATE246194T1 (de) 2003-08-15
DE69700321T2 (de) 1999-11-04
IL125411A0 (en) 1999-03-12
MX9704433A (es) 1998-11-30
CA2207694C (fr) 1999-11-23
IS4503A (is) 1997-12-15
HU9701048D0 (en) 1997-08-28
CA2207694A1 (fr) 1997-12-14
YU25497A (sh) 1998-12-23
SA97180124A (ar) 2005-12-03
SK283894B6 (sk) 2004-04-06
UY24585A1 (es) 1997-12-02
PE1299A1 (es) 1999-01-13
GR3031087T3 (en) 1999-12-31
EP0916675A2 (fr) 1999-05-19
RS20060484A (en) 2007-04-10
EP0812845A1 (fr) 1997-12-17
IL121000A0 (en) 1997-11-20
ID18745A (id) 1998-05-07
BG101569A (en) 1998-01-30
UY24612A1 (es) 2000-09-29
SI0812845T1 (en) 1999-12-31
ES2134051T3 (es) 1999-09-16
IN187350B (fr) 2002-03-30
IL121000A (en) 2000-02-29
CZ181197A3 (cs) 1998-03-18
HK1033459A1 (en) 2001-08-31
HRP970326B1 (en) 2000-10-31
ZA975259B (en) 1997-12-15
SG50024A1 (en) 1998-06-15
RS49653B (sr) 2007-09-21
AP717A (en) 1999-01-04
AR003401A1 (es) 1998-08-05
NO304551B1 (no) 1999-01-11
DE69723846D1 (de) 2003-09-04
SI0916675T1 (en) 2003-12-31
SA97180124B1 (ar) 2006-02-08
GB9612514D0 (en) 1996-08-14
OA10426A (en) 2001-12-07
AU2487897A (en) 1997-12-18
US6066735A (en) 2000-05-23
JP2866841B2 (ja) 1999-03-08
SK283896B6 (sk) 2004-04-06
DK0916675T3 (da) 2003-10-27
RS49924B (sr) 2008-09-29
HUP9701048A2 (hu) 1998-12-28
CN1168376A (zh) 1997-12-24
CN1106399C (zh) 2003-04-23
NO985064L (no) 1997-12-15
DE69723846T2 (de) 2004-03-04
EP0812845B1 (fr) 1999-07-14
DZ2247A1 (fr) 2002-12-18
JP3058863B2 (ja) 2000-07-04
TR199700470A2 (xx) 1998-01-21
US5955611A (en) 1999-09-21
SK74397A3 (en) 1998-06-03
IN187319B (fr) 2002-03-23
HRP970326A2 (en) 1998-06-30
ATE182150T1 (de) 1999-07-15
CN1149206C (zh) 2004-05-12
JPH11171879A (ja) 1999-06-29
EG24123A (en) 2008-07-06
SK283893B6 (sk) 2004-04-06
PL189333B1 (pl) 2005-07-29
IS6634A (is) 2002-11-25
NO306115B1 (no) 1999-09-20

Similar Documents

Publication Publication Date Title
AR026660A2 (fr)
BRPI9713914B8 (fr)
IN187317B (fr)
BR7600721U (fr)
BR7601346U (fr)
BR9603859A (fr)
CN3039213S (fr)
CN3040367S (fr)
CN3040543S (fr)
CN3040805S (fr)
CN3041207S (fr)
CN3041374S (fr)
CN3041383S (fr)
CN3042289S (fr)
CN3043305S (fr)
CN3044168S (fr)
CN3044346S (fr)
CN3044347S (fr)
CN3044348S (fr)
CN3044349S (fr)
CN3045208S (fr)
CN3045530S (fr)
CN3045806S (fr)
CN3045853S (fr)
CN3045880S (fr)